MidWest Drug Development Conference
ONLINE EVENT | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • 2021 Program
  • Flyer
  • 2021 Schedule
  • 2019 Program
  • 2018 Program
  • Map & Other Info (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

New treatment for Status Epilepticus ‘starves’ problematic neurons

University of Wisconsin (WARF)

This technology uses 2-deoxy-D-glucose (2DG) as a novel treatment for Status Epilepticus (SE).

2DG is a glucose analog that blocks glycolysis and subsequently stops SE by “starving” the neurons causing seizures. In response to cellular energy demand, neuronal glucose transporters uptake both glucose and 2DG; however, 2DG cannot undergo isomerization and thereby inhibits the subsequent steps of glycolysis necessary for neuronal energy production. The 2DG compound differs from glucose only by removal of an oxygen atom at the 2-position.

Like glucose, 2DG undergoes cellular uptake through glucose transporters in response to cellular energy demand followed by phosphorylation at the 6-position, but unlike glucose-6-phosphate, 2DG-6-phosphate cannot undergo isomerization, and thereby reversibly inhibits subsequent steps of glycolysis. 2DG offers the opportunity of a novel mechanism of action compared to all marketed anticonvulsants, particularly with its property of focal enhanced delivery to regions of brain circuitry experiencing seizure activity. The latter mechanism is likely to be very effective for treatment of SE, which dramatically increases 2DG uptake due to enhanced focal glucose metabolism in the brain regions driving SE.

Additionally, 2DG activity is independent of the extracellularly available concentration of GABA receptors, thereby offering possibility to overcome the time limitation associated with GABA receptor internalization after SE onset.

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
An Online Event
Oct. 4-5, 2021

Latest News
  • Presentation schedule set for 2021 September 21, 2021
  • MWDD moves to a virtual event in 2021 August 17, 2021
  • Sponsorship, presentation slots nearly full July 29, 2021
  • Registrations are now open for 2021 March 25, 2021
Twitter Hightlights
  • Today's the day!
    491 days ago
  • Schedule is set for the 2021 MidWest Drug Development Conference. Register today! https://t.co/5SvzL4EhuV
    504 days ago
  • No surprise to see some incredible innovations out of @UWMadison that could change drug delivery approaches, cancer… https://t.co/h90yfHwC5k
    505 days ago

Follow us! @DrugMw